Skip to main content
. 2019 Jul 17;154(9):800–809. doi: 10.1001/jamasurg.2019.1742

Table 1. Baseline Characteristics by Statusa.

Characteristic Participated in Lymphedema Substudy (n = 486) Not Included in This Analysis (n = 215) P Value
Age, mean (SD), y 50.1 (10.8) 51.1 (11.4) .25
Race
White 391 (80.4) 174 (80.9) .15
Black 71 (14.6) 28 (13.0)
Asian 15 (3.1) 4 (1.9)
Native American 0 2 (0.9)
>1 Race 0 1 (0.5)
Unknown or not reported 9 (1.8) 6 (2.8)
Ethnicity
Hispanic or Latino 42 (8.6) 24 (11.2) .40
Not Hispanic or Latino 418 (86.0) 183 (85.1)
Unknown or not reported 26 (5.4) 8 (3.7)
Baseline performance status
0 385 (79.2) 177 (82.3) .59
1 100 (20.6) 38 (17.7)
2 1 (0.2) 0
Smoking status
Current 56 (11.5) 29 (13.5) .16
Never 342 (70.4) 139 (64.6)
Past 74 (15.2) 34 (15.8)
Unknown 14 (2.9) 13 (6.0)
Diabetes
No 443 (91.2) 201 (93.5) .30
Yes 43 (8.8) 14 (6.5)
Peripheral vascular disease
No 484 (99.6) 213 (99.1) .59
Yes 2 (0.4) 2 (0.9)
Arthritis
No 447 (92.0) 206 (95.8) .06
Yes 39 (8.0) 9 (4.2)
Cardiac disease
No 356 (73.2) 166 (77.2) .27
Yes 130 (26.8) 49 (22.8)
Neoadjuvant chemotherapy regimen
Anthracycline-containing regimen 23 (4.7) 21 (9.8) .08
Taxane-containing regimen 84 (17.3) 38 (17.7)
Anthracycline- and taxane-containing regimen 371 (76.3) 152 (70.7)
Other 8 (1.6) 4 (1.9)
BMI categoryb
<25 137 (28.3) 59 (27.4) .06
25-29.99 127 (26.2) 78 (36.3)
30-34.99 118 (24.4) 40 (18.6)
35-39.99 62 (12.8) 26 (12.1)
≥40 40 (8.3) 12 (5.6)
Estrogen receptor status
Positive 299 (61.5) 128 (59.5) .73
Negative 186 (38.3) 87 (40.5)
Not done 1 (0.2) 0
Progesterone receptor status
Positive 253 (52.1) 110 (51.2) .76
Negative 232 (47.7) 104 (48.4)
Not done 1 (0.2) 1 (0.5)
Tumor biologyc
HR positive/ERBB2 negative 225 (46.6) 92 (42.8) .55
ERBB2 positive 141 (29.2) 71 (33.0)
Triple negative 117 (24.2) 52 (24.2)
T stage
T0 6 (1.2) 0 .55
Tis 1 (0.2) 1 (0.5)
T1 61 (12.6) 29 (13.5)
T2 270 (55.6) 115 (53.5)
T3 127 (26.1) 58 (27.0)
T4 21 (4.3) 12 (5.6)
N stage
N1 460 (94.6) 203 (94.4) .90
N2 26 (5.4) 12 (5.6)
Radiotherapy receivedd
Yes 416 (87.0) 175 (81.4) .053
No 62 (13.0) 40 (18.6)

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).

a

Data are presented as number (percentage) of patients unless otherwise indicated.

b

Data for 2 participants in the lymphedema substudy were unknown or not reported; thus, n = 484.

c

Data for 3 participants in the lymphedema substudy were unknown or not reported; thus, n = 483.

d

Data for 8 participants in the lymphedema substudy were unknown or not reported; thus, n = 478.